CIK: 0001910264
Total reported value
$915.4M
Reporting period: 2026-03-31 · Number of holdings: 14
SR One Capital Management, LP disclosed 14 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $915.4M and a quarterly turnover rate of 56.7%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "S"
SR One Capital Management, LP's disclosed holdings carry a Herfindahl concentration index of 0.153 — mathematically equivalent to about 7 equally-sized positions, well below its 14 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes are fairly uniform across the portfolio (a coefficient of variation of 1.11), suggesting a disciplined, rules-based approach to how much capital goes into each idea.
Recent activity leans toward initiating meaningfully larger new positions than it adds to existing ones (a 16.6 percentage-point tilt) — a pattern consistent with a more contrarian, new-idea-driven approach.
Sector classification currently covers about 11% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim ZBIO
0.0% -$84.4M
Add ACLXGBX
0.0% $116.4M
Trim CRSP
0.0% -$9.9M
Trim MLYS
0.0% -$14.4M
Trim SPRY
0.0% -$14.5M
Add ALMS
0.0% $24.0M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ACLXGBX | Arcellx INC | Stock-Other | 29.43% | +7.77% | — | |
| 2 | MANE | Veradermics INC | Stock-Other | 16.57% | +16.57% | NEW | |
| 3 | ZBIO | Zenas Biopharma INC | Stock-Other | 10.76% | -15.14% | — | |
| 4 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 10.59% | -4.55% | — | |
| 5 | DSGN | Design Therapeutics INC | Stock-Other | 7.59% | -1.08% | — | |
| 6 | ORIC | Oric Pharmaceuticals INC | Stock-Other | 6.39% | +1.05% | — | |
| 7 | ALMS | Alumis INC | Stock-Other | 4.72% | +2.01% | — | |
| 8 | MLYS | Mineralys Therapeutics INC | Stock-Other | 4.63% | -3.40% | — | |
| 9 | SPRY | Ars Pharmaceuticals INC | Stock-Other | 3.52% | -3.10% | — | |
| 10 | ORKA | Oruka Therapeutics INC | Stock-Other | 2.31% | +0.46% | — | |
| 11 | OCS | Oculis Holding AG | Stock-Other | 1.86% | +0.05% | — | |
| 12 | NKTX | Nkarta INC | Stock-Other | 0.77% | -0.10% | — | |
| 13 | ✓ | Engene Holdings INC | Stock-Other | 0.56% | -0.40% | — | |
| 14 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.32% | -0.13% | — |
Performance for Q3 2026
+13.4%
Performance Last 4 Quarters
-12.4%
Based on 52% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 14 | $915.4M | 57 | |
| 2025-12-31 | 13 | $706.4M | 32 | |
| 2025-09-30 | 12 | $691.4M | 59 | |
| 2025-06-30 | 13 | $461.4M | 0 | |
| 2025-03-31 | 12 | $389.3M | 0 | |
| 2024-12-31 | 11 | $410.1M | 0 | |
| 2024-09-30 | 11 | $498.7M | 0 | |
| 2024-06-30 | 9 | $319.4M | 0 | |
| 2024-03-31 | 6 | $364.1M | 0 | |
| 2023-12-31 | 5 | $238.2M | 0 | |
| 2023-09-30 | 6 | $195.1M | 0 | |
| 2023-06-30 | 6 | $231.9M | 0 | |
| 2023-03-31 | 6 | $268.5M | 0 | |
| 2022-12-31 | 5 | $273.9M | 0 | |
| 2022-09-30 | 4 | $218.7M | 0 | |
| 2022-06-30 | 4 | $204.3M | 0 | |
| 2022-03-31 | 3 | $195.3M | 0 | |
| 2021-12-31 | 2 | $177.0M | 0 | 1DSGN228202V |
SR One Capital Management, LP's most significant position changes for 2026-03-31: New buy: Veradermics INC (MANE).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ACLXGBX | Arcellx INC | +7.8% | — | Unchanged |
| 2 | ALMS | Alumis INC | +2% | — | Unchanged |
| 3 | ORIC | Oric Pharmaceuticals INC | +1.1% | — | Unchanged |
| 4 | ORKA | Oruka Therapeutics INC | +0.5% | — | Unchanged |
| 5 | OCS | Oculis Holding AG | +0.1% | — | Unchanged |
| 6 | NKTX | Nkarta INC | -0.1% | — | Unchanged |
| 7 | RARE | Ultragenyx Pharmaceutical In | -0.1% | — | Unchanged |
| 8 | ✓ | Engene Holdings INC | -0.4% | — | Unchanged |
| 9 | DSGN | Design Therapeutics INC | -1.1% | — | Unchanged |
| 10 | SPRY | Ars Pharmaceuticals INC | -3.1% | — | Unchanged |
| 11 | MLYS | Mineralys Therapeutics INC | -3.4% | — | Unchanged |
| 12 | CRSP | CRISPR Therapeutics AG | -4.6% | — | Unchanged |
| 13 | ZBIO | Zenas Biopharma INC | -15.1% | — | Unchanged |
| 14 | MANE | Veradermics INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-14 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-12 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-12 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-13 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-13 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-13 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-13 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-13 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-12 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-13 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-10 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-19 | Amendment | View on EDGAR |
| 2023-03-31 | 2023-05-09 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-08 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-08 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-02 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-10 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001473429
Total reported value
$915.1M
27 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001776033
Total reported value
$914.8M
1,666 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0001528086
Total reported value
$916.3M
66 stks
2015-09-30
Stale — no recent filing
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0000882095
Total reported value
$2.1B
6 stks
2026-03-31
1 of the top 5 holdings overlap, including Arcellx INC
CIK 0001131399
Total reported value
$599.2M
13 stks
2026-03-31
1 of the top 5 holdings overlap, including CRISPR Therapeutics AG
CIK 0001143261
Total reported value
$187.1M
81 stks
2026-03-31
1 of the top 5 holdings overlap, including Arcellx INC